THRX Insider Trading Activity and SEC Form 4 Filings
THRX insider trading summary
No open-market insider purchases or sales of Theseus Pharmaceuticals, Inc. (THRX) have been reported on SEC Form 4 in the past 12 months.
Latest THRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 17, 2023 | OrbiMed Genesis GP LLC | Director | Buy | $1.0M (328,482 @ $3.05) |
| Jul 17, 2023 | OrbiMed Genesis GP LLC | Director | Buy | $462K (151,450 @ $3.05) |
| Jul 17, 2023 | OrbiMed Capital GP VII LLC | Director | Buy | $1.0M (328,482 @ $3.05) |
| Jul 17, 2023 | OrbiMed Capital GP VII LLC | Director | Buy | $462K (151,450 @ $3.05) |
| Jul 17, 2023 | Orbimed Advisors LLC | Director | Buy | $462K (151,450 @ $3.05) |
| Jul 17, 2023 | Carl L Gordon | Director | Buy | $1.0M (328,482 @ $3.05) |
| Jul 17, 2023 | Carl L Gordon | Director | Buy | $462K (151,450 @ $3.05) |
| Jul 17, 2023 | Foresite Capital Opportunity Fund V, L.P. | 10% Owner | Buy | $1.6M (523,450 @ $2.97) |
| Jul 17, 2023 | Foresite Capital Management V, LLC | 10% Owner | Buy | $1.6M (523,450 @ $2.97) |
| Jul 17, 2023 | Orbimed Advisors LLC | Director | Buy | $1.0M (328,482 @ $3.05) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.